
Sangamo's ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
Sangamo Therapeutics’ investigational gene therapy isaralgagene civaparvovec improved kidney function in patients with Fabry disease, according to a Phase I/II readout from the company on Tuesday. Sangamo plans to use these results to build a case for …